These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34382352)

  • 21. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.
    Hammerer P; Al-Batran SE; Windemuth-Kieselbach C; Keller M; Hofheinz RD
    World J Urol; 2018 Mar; 36(3):375-381. PubMed ID: 29305637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
    Rouyer M; Oudard S; Joly F; Fizazi K; Tubach F; Jove J; Lacueille C; Lamarque S; Guiard E; Balestra A; Droz-Perroteau C; Fourrier-Reglat A; Moore N;
    Br J Cancer; 2019 Dec; 121(12):1001-1008. PubMed ID: 31719685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
    Bando Y; Hinata N; Terakawa T; Furukawa J; Harada KI; Nakano Y; Fujisawa M
    Med Oncol; 2017 Aug; 34(9):163. PubMed ID: 28819719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program.
    Lee JL; Park SH; Koh SJ; Lee SH; Kim YJ; Choi YJ; Lee J; Lim HY
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1005-13. PubMed ID: 25193433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
    BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.
    Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
    Anticancer Res; 2019 Aug; 39(8):4411-4414. PubMed ID: 31366538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.
    Di Lorenzo G; Pagliuca M; Perillo T; Benincasa A; Bosso D; De Placido S; Buonerba C
    Medicine (Baltimore); 2016 Apr; 95(14):e2754. PubMed ID: 27057826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.
    Robin G; Basappa NS; North S; Ghosh S; Kolinsky M
    Curr Oncol; 2024 Aug; 31(9):5080-5087. PubMed ID: 39330003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
    Caffo O; Wissing M; Bianchini D; Bergman A; Thomsen FB; Schmid S; Yu EY; Bournakis E; Sella A; Zagonel V; De Giorgi U; Tucci M; Gelderblom H; Galli L; Pappagallo G; Bria E; Sperduti I; Oudard S;
    Clin Genitourin Cancer; 2020 Feb; 18(1):69-76.e4. PubMed ID: 31767448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.
    Kosaka T; Shinojima T; Morita S; Oya M
    Cancer Sci; 2018 May; 109(5):1570-1575. PubMed ID: 29493842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
    Wissing MD; van Oort IM; Gerritsen WR; van den Eertwegh AJ; Coenen JL; Bergman AM; Gelderblom H
    Clin Genitourin Cancer; 2013 Sep; 11(3):238-250.e1. PubMed ID: 23659772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
    Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
    Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
    Aggarwal R; Bryce A; Ryan CJ; Harzstark A; Derleth C; Kim W; Friedlander T; Lin AM; Rodvelt-Bagchi T; Dhawan M; Zhang L; Lee M; Siebeneck E; Hough J; Small EJ
    Urol Oncol; 2017 Apr; 35(4):149.e7-149.e13. PubMed ID: 28161323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).
    Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullén A
    Eur J Cancer; 2018 Jul; 97():33-40. PubMed ID: 29685343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).
    Süner A; Aydın D; Hacıoğlu MB; Doğu GG; İmamoğlu GI; Menekşe S; Pilancı KN; Yazıcı ÖK; Koca D; Karaağaç M; Akyol M; Akman T; Ergen S; Avcı N; Kaçan T; Bozkurt O; Kefeli U; Urakçı Z; Araz M; Arpacı E; Harputlu H; Sevinç A
    Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1238-43. PubMed ID: 27097941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
    Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
    BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
    Antonarakis ES; Tagawa ST; Galletti G; Worroll D; Ballman K; Vanhuyse M; Sonpavde G; North S; Albany C; Tsao CK; Stewart J; Zaher A; Szatrowski T; Zhou W; Gjyrezi A; Tasaki S; Portella L; Bai Y; Lannin TB; Suri S; Gruber CN; Pratt ED; Kirby BJ; Eisenberger MA; Nanus DM; Saad F; Giannakakou P;
    J Clin Oncol; 2017 Oct; 35(28):3181-3188. PubMed ID: 28632486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.